Skadden advised Terumo Corporation on the offering. Terumo Corporation, a leading medical device manufacturer, completed the ¥182.5 billion (approximately US$1.3 billion) Rule 144A/Regulation S secondary offering...
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here